{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:40:02Z","timestamp":1792453202974,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yangtze River Pharmaceutical Group Co, Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01186-0","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:53:15Z","timestamp":1784685195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-drug interaction between ticagrelor and fazamorexant: pharmacokinetic alterations in healthy subjects from a phase I, open-label, fixed-sequence study"],"prefix":"10.1186","volume":"27","author":[{"given":"Xingxing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"1186_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/NSS.S521578","volume":"17","author":"L Li","year":"2025","unstructured":"Li L, Xia M, Chen X, Wang F, Li J, Zhao N, Liu Z, Chen Y. Comparative effects of two acupuncture protocols in the management of chronic insomnia: a randomized controlled trial. Nat Sci sleep. 2025;17:1789\u2013803. https:\/\/doi.org\/10.2147\/NSS.S521578.","journal-title":"Nat Sci sleep"},{"issue":"9","key":"1186_CR2","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.sleep.2009.07.008","volume":"10","author":"MM Ohayon","year":"2009","unstructured":"Ohayon MM, Reynolds CF 3rd. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009;10(9):952\u201360. https:\/\/doi.org\/10.1016\/j.sleep.2009.07.008.","journal-title":"Sleep Med"},{"issue":"2","key":"1186_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","volume":"6","author":"MM Ohayon","year":"2002","unstructured":"Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97\u2013111. https:\/\/doi.org\/10.1053\/smrv.2002.0186.","journal-title":"Sleep Med Rev"},{"issue":"2","key":"1186_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","volume":"17","author":"CM Morin","year":"2022","unstructured":"Morin CM, Jarrin DC. Epidemiology of insomnia: prevalence, course, risk Factors, and public health burden. Sleep Med Clin. 2022;17(2):173\u201391. https:\/\/doi.org\/10.1016\/j.jsmc.2022.03.003.","journal-title":"Sleep Med Clin"},{"issue":"5","key":"1186_CR5","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s11325-023-02812-5","volume":"27","author":"F Hasan","year":"2023","unstructured":"Hasan F, Lee HC, Chen PY, Wang YH, Yuliana LT, Romadlon DS, Tu YK, Chiu HY. Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysis. Sleep Breath. 2023;27(5):2021\u201330. https:\/\/doi.org\/10.1007\/s11325-023-02812-5.","journal-title":"Sleep Breath"},{"issue":"3","key":"1186_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1590\/1516-4446-2020-1651","volume":"44","author":"DF Curado","year":"2022","unstructured":"Curado DF, de Barros VV, Noto AR, Opaleye ES. Dependence on hypnotics: a comparative study between chronic users of benzodiazepines and Z-drugs. Brazilian J Psychiatry. 2022;44(3):248\u201356. https:\/\/doi.org\/10.1590\/1516-4446-2020-1651.","journal-title":"Brazilian J Psychiatry"},{"issue":"1","key":"1186_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12916-024-03437-5","volume":"22","author":"IV Hofe","year":"2024","unstructured":"Hofe IV, Stricker BH, Vernooij MW, Ikram MK, Ikram MA, Wolters FJ. Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study. BMC Med. 2024;22(1):266. https:\/\/doi.org\/10.1186\/s12916-024-03437-5.","journal-title":"BMC Med"},{"key":"1186_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000514963","volume":"45","author":"Y Sun","year":"2021","unstructured":"Sun Y, Tisdale RK, Kilduff TS. Hypocretin\/orexin receptor pharmacology and sleep phases. Front Neurol Neurosci. 2021;45:22\u201337. https:\/\/doi.org\/10.1159\/000514963.","journal-title":"Front Neurol Neurosci"},{"issue":"34","key":"1186_CR9","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.3760\/cma.j.cn112137-20250421-00981","volume":"105","author":"Chinese Sleep Research Society","year":"2025","unstructured":"Chinese Sleep Research Society. Guidelines for the diagnosis and treatment of insomnia disorder (2025 edition). Zhonghua yi xue za zhi. 2025;105(34):2960\u201381. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20250421-00981.","journal-title":"Zhonghua yi xue za zhi"},{"key":"1186_CR10","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.2147\/DDDT.S501111","volume":"19","author":"J Ni","year":"2025","unstructured":"Ni J, Jin L, Zhao D, Zhang W, Li B, Huang X, Hao X. Pharmacokinetics, pharmacodynamic, safety and tolerability of fazamorexant, a novel dual orexin receptor antagonist: report of the first-in-human study. Drug Des Devel Ther. 2025;19:5271\u201382. https:\/\/doi.org\/10.2147\/DDDT.S501111.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"1186_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703\u201310. https:\/\/doi.org\/10.1124\/dmd.110.037143.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1186_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3760\/cma.j.cn112138-20200420-00398","volume":"60","author":"Y Kong","year":"2021","unstructured":"Kong Y, Ding RJ, Lei S, Wang L, Xia K, Jiang HY, Zhang LJ, Yao DK, Ma WL, Hu DY. An analysis of insomnia and its influencing factors in patients with acute coronary syndrome. Zhonghua nei ke za zhi. 2021;60(4):331\u20137. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200420-00398.","journal-title":"Zhonghua nei ke za zhi"},{"key":"1186_CR13","unstructured":"AstraZeneca AB. Ticagrelor(BRILINTA) tablets:package insert [Internet]. Beijing: National Medical Products Administration; 2017. https:\/\/zy.yaozh.com\/instruct\/sms20190318\/0d585a41f28537dc0cb07c4f2f5217b1.pdf."},{"issue":"5","key":"1186_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40262-023-01245-3","volume":"62","author":"L Ortega-Paz","year":"2023","unstructured":"Ortega-Paz L, Giordano S, Franchi F, Rollini F, Pollack CV Jr, Bhatt DL, Angiolillo DJ. Clinical and pre-clinical pharmacokinetics and pharmacodynamics of bentracimab. Clin Pharmacokinet. 2023;62(5):673\u201392. https:\/\/doi.org\/10.1007\/s40262-023-01245-3.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1186_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(3):477\u201387. https:\/\/doi.org\/10.1007\/s00228-012-1369-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1186_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/PRA.0000000000000690","volume":"29","author":"SH Preskorn","year":"2023","unstructured":"Preskorn SH. Comparative pharmacology of the 3 marketed dual orexin antagonists-daridorexant, lemborexant, and suvorexant-part 2. Principal Drug Metabolizing Enzyme, Drug-Drug Interactions, and Effects of Liver and Renal Impairment on Metabolism. J Psychiatr Pract. 2023;29(1):38\u201341. https:\/\/doi.org\/10.1097\/PRA.0000000000000690.","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"1186_CR17","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.3892\/mmr.2019.10692","volume":"20","author":"B Zhang","year":"2019","unstructured":"Zhang B, Zhan G, Fang Q, Wang F, Li Y, Zhang Y, Zhao L, Zhang G, Li B. Evaluation of cytochrome P450 3A4\u2013mediated drug\u2013drug interaction potential between P2Y12 inhibitors and statins. Mol Med Rep. 2019;20(5):4713\u201322. https:\/\/doi.org\/10.3892\/mmr.2019.10692.","journal-title":"Mol Med Rep"},{"key":"1186_CR18","unstructured":"U.S. Food and Drug Administration. Guidance for industry: clinical drug interaction studies-cytochrome P450 enzyme and transporter-mediated drug interactions, 2020. http:\/\/resource.nlm.nih.gov\/101767654."},{"key":"1186_CR19","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"1186_CR20","unstructured":"National Medical Products Administration. Technical guidance for drug-drug interaction studies (Trial implementation). 2021. https:\/\/www.cde.org.cn\/main\/att\/download\/3cd327dd420cf231b87021d295bebe80."},{"issue":"6","key":"1186_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/cpdd.915","volume":"10","author":"I Landry","year":"2021","unstructured":"Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, Dayal S, Filippov G, Lalovic B, Moline M, Reyderman L. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmacol drug Dev. 2021;10(6):681\u201390. https:\/\/doi.org\/10.1002\/cpdd.915.","journal-title":"Clin Pharmacol drug Dev"},{"key":"1186_CR22","unstructured":"U.S. Food and Drug Administration. Integrated review- daridorexant (QUVIVIQ), 240. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214985Orig1s000IntegratedR.pdf."},{"issue":"5","key":"1186_CR23","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/bcp.70414","volume":"92","author":"C Xia","year":"2026","unstructured":"Xia C, Xingxing H, Lu J, Ruwei W. Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse. British journal of clinical pharmacology. Br J Clin Pharmacol. 2026;92(5):1473\u201386. https:\/\/doi.org\/10.1002\/bcp.70414.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01186-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:56:25Z","timestamp":1792450585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01186-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This open-label, non-randomized, sequential dosing study was performed with the approval of the Ethical Committee of Shulan (Hangzhou) Hospital, China (YW2024-037-01, 11 July 2024). All procedures were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice (GCP). Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"145"}}